Come and join us on 6 July and hear 4 AIM CEO’s speak. Brad George, Orosur CEO updates us on Colombia’s Tier-1 gold mine potential, Cliff Gross, CEO at Tekcapital explains how investors benefit from a special dividend. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAmryt Pharma Share News (AMYT)

Share Price Information for Amryt Pharma (AMYT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 166.00
Bid: 165.00
Ask: 170.00
Change: -1.50 (-0.90%)
Spread: 5.00 (3.03%)
Open: 167.50
High: 166.00
Low: 166.00
Yest. Close: 167.50
AMYT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

RNS Alerts are a premium feature

Login to your account

myTerminal is a premium feature

Login to your account

Don't have an account? Click here to register.

EXECUTIVE CHANGES: Rosslyn promotes new CEO; Celtic CEO ready to start

Tue, 6th Apr 2021 14:54

(Alliance News) - The following is a round-up of London-listed company director and manager changes announced on Tuesday and not separately reported by Alliance News:



GlaxoSmithKline PLC - Brentford, Middlesex-based pharmaceutical firm - Hires Anne Beal as non-executive director, starting May 6. Beal will replace Lynn Elsenhans as chair of the Corporate Responsibility Committee, and Elsenhans will stay on the board for an additional year to allow for a handover. Beal is founder and chief executive officer of AbsoluteJOI Skincare. She spent six years at Harvard Medical School and Massachusetts General Hospital, instructing in paediatrics.



Assura PLC - Warrington, England-based primary care property investor - Jenefer Greenwood will retire as non-executive director at Assura's July 6 annual general meeting. Hires Emma Cariaga, Noel Gordon and Sam Barrell as new non-executive directors, starting on May 1. Cariaga is joint head of Canada Water Development on the executive committee of British Land Co PLC. Gordon was global managing director at consultants Accenture. For the UK National Health Service, he was chair of NHS Digital and a non-executive director of NHS England. Barrell is chief operating officer of the Crick Institute, which supports biomedical research.



Rosslyn Data Technologies PLC - London-based cloud enterprise data analytics platform - Chief Executive Officer Roger Bullen steps down from board, effective immediately, but will remain as an adviser for six months. Bullen served for five years as CEO and chief financial officer. Chief Customer Officer Paul Watts is promoted to CEO. Watts joined Rosslyn back in August and before that was CEO of Blue Prism KK Japan, a robotic process automation company. Both Chair James Appleby and CFO Ash Mehta will take on additional responsibilities. Rosslyn also says it expects its results for the financial year ending April 30 to be in line with market expectations. It will issue a trading update in late May.



Celtic PLC - Glasgow football club - Confirms that Dominic McKay will join Celtic on April 19 before replacing retiring Peter Lawwell as chief executive on July 1. Scottish Rugby confirmed that McKay will leave as chief operating officer on April 16, following a successful handover. McKay, who also was chair of the Guinness Pro14 annual rugby union competition, will join the Celtic board.



Amryt Pharma PLC - London-based biopharmaceutical firm focused on rare and orphan diseases - Hires Sheila Frame as president for the Americas. Frame has held senior positions at Novartis AG, Bristol-Myers Squibb Co and AstraZeneca PLC.



MyHealthChecked PLC - Cardiff-based consumer home-testing healthcare - Peter Dines steps down as non-executive director on Tuesday. Dines is chief operating officer of Mercia Asset Management PLC, whose funds have a 28% stake in MyHealthChecked. He is standing down to focus on other portfolio companies.



Northamber PLC - Chessington, Surrey-based audio-visual and information technology distributor - Promotes Finance Director Tony Lee to board and hires Riccardo Reggio as a non-executive director, both from last Thursday. Lee re-joined Northamber in August of last year, having previously been finance director from 2003 to 2005. Reggio is a corporate strategy and acquisitions adviser who worked at Monitor Group for 15 years.



By Tom Waite; thomaslwaite@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News

Cathal Friel-led Poolbeg Pharma set to float on AIM

(Sharecast News) - Infectious disease specialist Poolbeg Pharma is to list on the London Stock Exchange's junior market, AIM, with a view to raising the funds needed to develop its product pipeline.

17 Jun 21 14:34

BUSINESS UPDATES: HSBC issues notes; discoverIE reports profit fall

BUSINESS UPDATES: HSBC issues notes; discoverIE reports profit fall

3 Jun 21 19:20

FDA grants Amryt's Oleogel-S10 priority review status

(Sharecast News) - Commercial-stage biopharmaceutical company Amryt Pharma announced on Thursday that the United States Food and Drug Administration (FDA) has granted priority review status for the new drug application for 'Oleogel-S10', for the treatment of epidermolysis bullosa (EB).

3 Jun 21 11:26

TRADING UPDATES: Block Energy 2020 revenue jumps; Kanabo loss narrows

TRADING UPDATES: Block Energy 2020 revenue jumps; Kanabo loss narrows

2 Jun 21 19:10

TRADING UPDATES: SIG in good start to 2021; Accsys taps EUR37 million

TRADING UPDATES: SIG in good start to 2021; Accsys taps EUR37 million

5 May 21 19:20

EXECUTIVE CHANGES: Rosslyn promotes new CEO; Celtic CEO ready to start

EXECUTIVE CHANGES: Rosslyn promotes new CEO; Celtic CEO ready to start

6 Apr 21 14:54

Amryt completes rolling FDA submission for Oleogel-S10

(Sharecast News) - Commercial-stage biopharmaceutical company Amryt Pharma has completed the rolling submission of a new drug application (NDA) to the US Food and Drug Administration (FDA) for 'Oleogel-S10', it announced on Wednesday, for the potential treatment of cutaneous manifestations of junctional and dystrophic epidermolysis bullosa (EB).

31 Mar 21 11:50

Amryt releases data from Italy lomitapide study

(Sharecast News) - Commercial-stage biopharmaceutical company Amryt Pharma released efficacy and safety data from the 'Lochnes' investigator-sponsored study of lomitapide in familial chylomicronemia syndrome (FCS) on Tuesday, which was conducted by expert lipidologists in Italy.

30 Mar 21 12:11

European approval for Amryt's Oleogel-S10 moves closer

(Sharecast News) - Commercial-stage biopharmaceutical company Amryt Pharma announced the validation of its marketing authorisation application for 'Oleogel-S10' by the European Medicines Agency on Monday, for the potential treatment of cutaneous manifestations of junctional and dystrophic epidermolysis bullosa.

29 Mar 21 09:15

IN BRIEF: Amryt gets positive feedback on Myalept from US regulator

IN BRIEF: Amryt gets positive feedback on Myalept from US regulator

23 Mar 21 19:03

Amryt upbeat on positive FDA feedback

(Sharecast News) - Commercial-stage biopharmaceuticals company Amryt Pharma has received further feedback from the United States Food and Drug Administration (FDA) on Myalept, it said on Tuesday, and its proposed development plan and study design to support an indication for patients with partial lipodystrophy (PL).

23 Mar 21 09:34

IN BRIEF: Amryt's Myalepta secures reimbursement approval in France

IN BRIEF: Amryt's Myalepta secures reimbursement approval in France

22 Mar 21 19:07

Amryt's Myalepta gets reimbursement approval in France

(Sharecast News) - Commercial-stage biopharmaceuticals company Amryt Pharma announced on Monday that the French Ministry of Social Affairs and Health has approved 'Myalepta', or metreleptin, for reimbursement in the country as an adjunct to diet as replacement therapy.

22 Mar 21 09:04

Director dealings: Amryt Pharma chairman makes share purchase

(Sharecast News) - Amryt Pharma revealed on Monday that chairman Ram Stafford had acquired 300,100 ordinary shares in the AIM-listed commercial-stage biopharmaceutical company.

15 Mar 21 16:38

IN BRIEF: Amryt, Medison sign distribution deal for Myalepta in Canada

IN BRIEF: Amryt, Medison sign distribution deal for Myalepta in Canada

9 Mar 21 06:55

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.